Abstract:Engineered monoclonal antibodies (mAbs) have proven to be highly effective therapeutics in recent viral outbreaks due to their specificity and ability to provide immediate protection, regardless of immune status. However, despite technical advancements in the field, an ability to rapidly adapt or increase antibody affinity and by extension, therapeutic efficacy, has yet to be fully realized. We endeavored to stand-up such a pipeline using molecular modeling combined with experimental library screening to increase the affinity of a given antibody, F5, to recombinant E1E2 antigen from Venezuelan Equine Encephalitis Virus (VEEV) subtype IAB (TC-83). F5 is a monoclonal antibody with potent neutralizing activity against VEEV that was isolated from human bone marrow donors. F5 is known to bind to spikes on the surface of VEEV made up of a trimer of heterodimers of the glycoproteins E1 and E2. In this work we modeled the interaction of F5 with the E1E2 trimer of VEEV (TC-83) and generated predictions for mutations to improve binding using a Rosetta-based approach and dTERMen, an informatics approach. Modeling the structure of the complex was complicated by the fact that a high-resolution structure of F5 is not available and the H3 loop of F5 exceeds the length for which current modeling approaches can determine a unique structure. To overcome these challenges nine F5 structures with varying H3 loop conformations were generated using RosettaAntibody, PIGS (Prediction of ImmunoGlobulin Structure), and SWISS-Model and these base antibody structures were evaluated in docking trials to recombinant VEEV E1E2 based on relative binding affinity for several subtypes. The structure that gave the best agreement with the experimental trend in relative binding affinity was used for mutation analysis. A subset of the predicted mutations from both methods were incorporated into a phage display library of scFvs (single-chain variable fragments) and screened for binding affinity to the recombinant E1E2 antigen. Results from this screen were used to identify favorable mutations which were then incorporated into twelve human-IgG1 variants. All twelve variants showed increased binding relative to the parental F5 human-IgG1. The best case showed > 60x increased binding to recombinant E1E2 relative to the parental antibody, notably showing a drastic improvement of the Kd or off rate compared to the parental F5 IgG. These results demonstrate the ability of our methods to rapidly increase affinity and could be leveraged for increasing Ab binding breadth to additional viral variants.

Binding Of The 2f5 Monoclonal Antibody To Native And Fusion-Intermediate Forms Of Human Immunodeficiency Virus Type 1 Gp41: Implications For Fusion-Inducing Conformational Changes

Multifaceted Consequences of Anti-Gp41 Monoclonal Antibody 2F5 Binding to HIV Type 1 Virions.

Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41.

Short Communication: in VitroSynergy Between Peptides or Neutralizing Antibodies Targeting the N- and C-Terminal Heptad Repeats of HIV Type 1 Gp41

Characterization of Antibody Responses Against the 2F5 Epitope ELDKWA sing HIV-1 Env-Mediated Membrane Fusion and Neutralization Assays

F(ab′)2 Fragment of a Gp41 NHR-trimer-induced IgM Monoclonal Antibody Neutralizes HIV-1 Infection and Blocks Viral Fusion by Targeting the Conserved Gp41 Pocket

Identification of Critical Antibody-Binding Sites in the HIV-1 Gp41 Six-Helix Bundle Core As Potential Targets for HIV-1 Fusion Inhibitors

A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein.

A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope.

Correction: HIV-1 Fusion is Blocked Through Binding of GB Virus C E2D Peptides to the HIV-1 Gp41 Disulfide Loop.

Fusion Peptide of HIV-1 As a Site of Vulnerability to Neutralizing Antibody

Molecular basis for epitope recognition by non-neutralizing anti-gp41 antibody F240

ELDKWA-epitope-specific monoclonal antibodies inhibit HIV env-mediated syncytium formation.

Determination of the HIV-1 gp41 fusogenic core conformation modeled by synthetic peptides: applicable for identification of HIV-1 fusion inhibitors.

HIV-1 Gp41 Fusion Intermediate: a Target for HIV Therapeutics.

The high-affinity immunoglobulin receptor FcγRI potentiates HIV-1 neutralization via antibodies against the gp41 N-heptad repeat

GPI-anchored single chain Fv - an effective way to capture transiently-exposed neutralization epitopes on HIV-1 envelope spike

A sequestered fusion peptide in the structure of an HIV-1 transmitted founder envelope trimer

Crystal Structure and Size-Dependent Neutralization Properties of HK20, a Human Monoclonal Antibody Binding to the Highly Conserved Heptad Repeat 1 of gp41

Combining computational modeling and experimental library screening to affinity-mature VEEV-neutralizing antibody F5

Conformational trajectory of the HIV-1 fusion peptide during CD4-induced envelope opening